Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.47 |
| ▸ | MTTP | P55157 | 10/20 | 0.42 |
| ▸ | APOB | P04114 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14735725 | 0.96 | MTTP (0.43) | NPY2RMTTPAPOBPOLBGAA | |
| SCHEMBL14735786 | 0.96 | MTTP (0.43) | NPY2RMTTPAPOBPOLBGAA | |
| SCHEMBL785011 | 0.88 | GAA (0.41) | MTTPAPOBPOLBGAAMMP2 | |
| SCHEMBL786257 | 0.88 | GAA (0.41) | MTTPAPOBPOLBGAAMMP2 | |
| Usistapide SCHEMBL803531 | 0.84 | NPY2R (0.62) | NPY2RMTTPAPOB | |
| Usistapide SCHEMBL803532 | 0.84 | NPY2R (0.62) | NPY2RMTTPAPOB | |
| Usistapide SCHEMBL785394 | 0.84 | NPY2R (0.62) | NPY2RMTTPAPOB | |
| Usistapide SCHEMBL29376869 | 0.84 | NPY2R (0.62) | NPY2RMTTPAPOB | |
| SCHEMBL13522123 | 0.79 | NPY2R (0.49) | NPY2RMTTP | |
| SCHEMBL13522099 | 0.79 | NPY2R (0.53) | NPY2RMTTPAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461341-B2 | Resolution of (±)-methyl phenyl[4-[4-[[[4′(trifluoromethyl)-2-biphenylyl]carbonyl]amino]Phenyl]-1-piperidinyl]acetate | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-11 | — | — | US | claimed |
| EP-2435406-B1 | RESOLUTION OF (±)-METHYL PHENYL[4-[4-[[[4'-(TRIFLUOROMETHYL)-2-BIPHENYLYL]CARBONYL]AMINO]PHENYL]-1-PIPERIDINYL]ACETATE | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-06 | — | — | EP | claimed |
| US-20120071660-A1 | RESOLUTION OF (±)-METHYL PHENYL[4-[4-[[[4'(TRIFLUOROMETHYL)-2- BIPHENYLYL]CARBONYL]AMINO]PHENYL]-1-PIPERIDINYL]ACETATE | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071660-A1 | RESOLUTION OF (±)-METHYL PHENYL[4-[4-[[[4'(TRIFLUOROMETHYL)-2- BIPHENYLYL]CARBONYL]AMINO]PHENYL]-1-PIPERIDINYL]ACETATE | MTTP, CETP, LIPC | NPY2R 4688/4885MTTP 1/4885APOB 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.